A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
暂无分享,去创建一个
C. Redmond | R. Foster | D. Wickerham | N. Wolmark | A. Glass | B. Fisher | R. Margolese | E. Fisher | N. Dimitrov | C. Sutherland | D. Bowman | R. Caplan | S. Legault-Poisson | N. Wolmark | Edwin R. Fisher | D. Lawrence Wigkerham
[1] F. Ederer,et al. Maximum utilization of the life table method in analyzing survival. , 1958, Journal of chronic diseases.
[2] C. Redmond,et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.
[3] J. Bertino,et al. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. , 1977, Cancer research.
[4] G. Heppner,et al. Effect of sequence of administration of methotrexate, leucovorin, and 5-fluorouracil on mammary tumor growth and survival in syngeneic C3H mice. , 1977, Cancer research.
[5] R. Heimer,et al. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. , 1979, Science.
[6] C. Redmond,et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.
[7] A. Gewirtz,et al. Preliminary report on the efficacy of sequential methotrexate and 5‐fluorouracil in advanced breast cancer , 1981, Cancer.
[8] H. Morgenstern,et al. Epidemiologic Research: Principles and Quantitative Methods. , 1983 .
[9] B Fisher,et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.
[10] N Breslow,et al. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. , 1986, Biometrics.
[11] V. Semiglazov,et al. Clinical trials on adjuvant chemotherapy for breast cancer , 1986, Cancer.
[12] C. Redmond,et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Redmond,et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.